We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Change in tack

31 March 2006 By Robert Cyran

After failing to sell itself for $15bn, the Swiss biotech is seeking permission to sell $5.5bn in new shares for acquisitions. But it hasn’t said it won’t sell itself if a bidder shows up. It seems Serono is trying to avoid being left embarrassingly on the shelf.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)